Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.

James AM, King JR, Ofotokun I, Sheth AN, Acosta EP.

J Exp Pharmacol. 2013 Aug 1;5:55-64. doi: 10.2147/JEP.S45308. eCollection 2013.

2.

Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts.

Nejati A, Shahmahmoodi S, Arefian E, Shoja Z, Marashi SM, Tabatabaie H, Mollaei-Kandelous Y, Soleimani M, Nategh R.

Exp Ther Med. 2016 May;11(5):1833-1838. Epub 2016 Mar 2.

3.

Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment.

Ogunwuyi O, Kumari N, Smith KA, Bolshakov O, Adesina S, Gugssa A, Anderson WA, Nekhai S, Akala EO.

Infect Dis (Auckl). 2016 Mar 20;9:21-32. doi: 10.4137/IDRT.S38108. eCollection 2016.

4.

Alcohol and HIV Effects on the Immune System.

Bagby GJ, Amedee AM, Siggins RW, Molina PE, Nelson S, Veazey RS.

Alcohol Res. 2015;37(2):287-97. Review.

5.

Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.

Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, Gatot JS, Melard A, Vanhulle C, Kabeya K, Pardons M, Avettand-Fenoel V, Clumeck N, De Wit S, Rohr O, Rouzioux C, Van Lint C.

EMBO Mol Med. 2015 Dec 17;8(2):117-38. doi: 10.15252/emmm.201505557.

6.
7.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.

8.

HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells.

Chavez L, Calvanese V, Verdin E.

PLoS Pathog. 2015 Jun 11;11(6):e1004955. doi: 10.1371/journal.ppat.1004955. eCollection 2015 Jun.

9.

Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.

Duwal S, Winkelmann S, Schütte C, von Kleist M.

PLoS Comput Biol. 2015 Apr 30;11(4):e1004200. doi: 10.1371/journal.pcbi.1004200. eCollection 2015 Apr.

10.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM.

J Infect Dis. 2015 Nov 1;212(9):1361-5. doi: 10.1093/infdis/jiv218. Epub 2015 Apr 15.

PMID:
25877550
11.

Metastasis prevention by targeting the dormant niche.

Ghajar CM.

Nat Rev Cancer. 2015 Apr;15(4):238-47. doi: 10.1038/nrc3910.

12.

Viremic relapse after HIV-1 remission in a perinatally infected child.

Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, Mellors JW, Rosenbloom D, Persaud D.

N Engl J Med. 2015 Feb 19;372(8):786-8. doi: 10.1056/NEJMc1413931. No abstract available.

13.

Human immunodeficiency virus (HIV)-1 integration sites in viral latency.

Rezaei SD, Cameron PU.

Curr HIV/AIDS Rep. 2015 Mar;12(1):88-96. doi: 10.1007/s11904-014-0241-9. Review.

14.

Contribution of HIV-1 genomes that do not integrate to the basic reproductive ratio of the virus.

Lau JW, Levy DN, Wodarz D.

J Theor Biol. 2015 Feb 21;367:222-9. doi: 10.1016/j.jtbi.2014.12.004. Epub 2014 Dec 12.

15.

Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents.

Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, Siberry GK, Van Dyke RB, Burchett S, Seage GR 3rd, Luzuriaga K; Pediatric HIV/AIDS Cohort Study.

JAMA Pediatr. 2014 Dec;168(12):1138-46. doi: 10.1001/jamapediatrics.2014.1560. Erratum in: JAMA Pediatr. 2015 Jan;169(1):96.

16.

Is the central nervous system a reservoir of HIV-1?

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ.

Curr Opin HIV AIDS. 2014 Nov;9(6):552-8. doi: 10.1097/COH.0000000000000108. Review.

17.

Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.

Edagwa BJ, Zhou T, McMillan JM, Liu XM, Gendelman HE.

Curr Med Chem. 2014;21(36):4186-98. Review.

18.

Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid.

McDonnel SJ, Liepnieks ML, Murphy BG.

Antiviral Res. 2014 Aug;108:74-8. doi: 10.1016/j.antiviral.2014.05.014. Epub 2014 Jun 2.

19.

HIV-1 latency in monocytes/macrophages.

Kumar A, Abbas W, Herbein G.

Viruses. 2014 Apr 22;6(4):1837-60. doi: 10.3390/v6041837. Review.

20.

Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system.

Gomes MJ, Neves Jd, Sarmento B.

Int J Nanomedicine. 2014 Apr 7;9:1757-69. doi: 10.2147/IJN.S45886. eCollection 2014. Review.

Items per page

Supplemental Content

Write to the Help Desk